NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Akari Therapeutics, Plc (AKTX) Stock Analysis

Akari Therapeutics, Plc (AKTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AKTX

$11.47

+$0.63 (+5.81%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AKTX with… →

AKTX Key Statistics

As of Sep 4, 2026
Trading
Open
$10.41
Previous Close
$10.84
Day's Range
10.17–11.82
52-Week Range
3.02–49.60
Volume
108.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.43
Valuation
Market Cap
$22.33M
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$17.30M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.95M
1-Year Return
−60.72%
Dividend and dates
Avg Volume
70.59K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AKTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−0.78%
2025−76.31%
2024−60.90%
2023−66.81%
2022−68.67%
2021−18.92%
2020+5.71%
2019+11.46%
2018−63.74%
2017−38.49%
2016 (partial year)−26.44%

As of September 4, 2026.

AKTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.30M—
2024$0.00−$19.79M—
2023$0.00−$10.01M—
2022$0.00−$17.75M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.10M−$17.30M—
2024$0.00—−$16.65M−$19.79M—
2023$0.00—−$16.81M−$10.01M—
2022$0.00—−$23.09M−$17.75M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AKTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricAKTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Akari Therapeutics, Plc (AKTX) is capitalised at $22.33M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 5 employees.

Over the past 52 weeks the price has ranged from $3.02 to $49.60. AKTX last closed at $11.47 on September 4, 2026. That is +$0.63 (+5.81%) against the previous close. The latest close sits 280.43% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $17.30M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 0.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Over the trailing twelve months the price has returned −60.72%. Across 10 years the annualized return works out at −47.55%. The reported beta is 1.43. Annualized volatility over the trailing 10 years is 146.2%.

Growth & Income

No dividend is on file for AKTX.

2026 is still running; the price is −0.78% year to date. The strongest complete calendar year on file is 2019 at +11.46%; the weakest is 2025 at −76.31%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Akari Therapeutics, Plc (AKTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Akari Therapeutics, Plc AKTX $22.33M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Akari Therapeutics, Plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Visit website →